ProCE Banner Activity

MPD-RC 112: Frontline Peginterferon α-2a vs Hydroxyurea in High-Risk Polycythemia Vera and Essential Thrombocythemia

Slideset Download
Conference Coverage
Results from interim analysis of phase III trial found no difference in CR at 12 months between therapies, and grade ≥ 3 AEs occurred more frequently in patients receiving pegIFN α-2a.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen